What is Aitia?
Aitia specializes in the application of Causal AI and Digital Twins to accelerate the discovery of novel drugs. By integrating multi-omic patient data with high-performance computing and causal learning, the company creates Digital Twins of diseases across oncology, neurodegenerative disorders, and immunology. These advanced digital models are currently employed to identify new therapies and expedite research and development for conditions such as multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional programs in progress. Aitias collaborative network includes seven of the top ten pharmaceutical companies, prominent academic research institutions, medical societies, leading multi-omic data providers, and global patient advocacy groups.
How much funding has Aitia raised?
Aitia has raised a total of $69.6M across 10 funding rounds:
Series B
$9.9M
Multiple Rounds
$18.9M
Private Equity
$4M
Private Equity
$6M
Series D
$23M
Debt
$1M
Debt
$1.8M
Series B (2013): $9.9M led by Mitsui & Co, Ltd., Heritage Provider Network, and Cambia Health Solutions
Debt (2015): $750K, investors not publicly disclosed
Private Equity (2015): $8.1M, investors not publicly disclosed
Series C (2015): $10M backed by Celgene Corporation, Alexandria Real Estate Equities, and Cambia Health Solutions
Private Equity (2016): $4M with participation from Echo Health Ventures
Private Equity (2017): $6M led by Alexandria Real Estate Equities
Series D (2019): $23M, investors not publicly disclosed
Debt (2020): $1M featuring PPP
Debt (2021): $1.8M backed by PPP
Key Investors in Aitia
Celgene Corporation
Celgene Corporation, a key backer, is a biopharmaceutical company known for its focus on developing innovative therapies for cancer and immune-inflammatory diseases.
Alexandria Real Estate Equities
Alexandria Real Estate Equities is a prominent real estate investment trust (REIT) that focuses on developing and managing high-quality scientific research facilities, often investing in life science companies.
Cambia Health Solutions
Cambia Health Solutions is a healthcare company that invests in and supports innovative solutions aimed at transforming the healthcare system and improving health outcomes.
What's next for Aitia?
With the recent strategic investment and substantial overall backing, Aitia is poised for significant expansion and innovation. The company's focus on creating Digital Twins of diseases, particularly in complex areas like oncology and neurodegenerative disorders, positions it at the forefront of pharmaceutical innovation. Future endeavors will likely involve scaling its AI-driven drug discovery platform, forging deeper partnerships with pharmaceutical giants, and potentially exploring new therapeutic areas. This strategic financing will be instrumental in advancing its pipeline and solidifying its market leadership in the application of causal AI for next-generation therapeutics.
See full Aitia company page
